Pidotimod

Pidotimod strengthens and stimulates the immune mechanisms involved in humoral immunity, and also those of cellular immunity mediated by T lymphocytes. At the same time, it increases the migration of macrophages. This is an essential, primary step in the cellular immune response, because it allows adequate phagocytosis and elimination of the infectious germ. The medicine has an effective protective and preventive action against infections by Gram positive and Gram-negative germs. This action doesn't come from any antimicrobial property of its own but from its immunostimulant effect. It is absorbed rapidly after oral administration. For the tablet, the mean peak plasma concentration is reached 1.5 hours after a dose in adults, and oral bioavailability was 42 to 44%. Food doesn't change the extent of absorption, but it delays absorption and lowers bioavailability by up to 50%. So it is recommended to take Pidotimod two hours before or two hours after food. It is widely distributed throughout the body and is almost completely absorbed when given by mouth. Very little of it is metabolised in the liver, and no metabolites are known. Binding to plasma proteins is very poor, which is an advantage because it does not interfere with other medicines. The half-life is approximately 4 hours. Most of the medicine leaves the body in the urine, and a small amount in the feces.